Association between CBR1 polymorphisms and NSCLC in the Chinese population

Guo,Yong; Shen,Yingying; Xia,Yongming; Gu,Jianzhong

doi:10.3892/ol.2017.6926

Association between CBR1 polymorphisms and NSCLC in the Chinese population

Authors:
- Yong Guo
- Yingying Shen
- Yongming Xia
- Jianzhong Gu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China, Department of Oncology, Yuyao People's Hospital of Zhejiang, Yuyao, Zhejiang 315400, P.R. China
Published online on: September 14, 2017 https://doi.org/10.3892/ol.2017.6926
Pages: 6291-6297

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carbonyl reductase 1 (CBR1) is theorized to participate in various cellular processes, such as signal transduction, apoptosis, carcinogenesis and drug resistance, and is highly expressed in certain malignancies, including lung tumors. Several studies have provided evidence that gene polymorphisms may affect susceptibility to non‑small cell lung cancer (NSCLC). The present study aimed to investigate the association between the CBR1 single‑nucleotide polymorphisms (SNPs) rs3787728 and rs2835267, and NSCLC in a Chinese population. The data indicated that the allele frequency in CBR1 rs3787728 was significantly different between patients with NSCLC and the controls [odds ratio (OR)=1.209; 95% confidence interval (CI)=1.013‑1.442; P=0.0349], and was significantly different between male patients with NSCLC and the corresponding controls (OR=1.278; 95% CI=1.016‑1.607; P=0.0358). The CBR1 rs3787728 thymine (T)/T allele homozygote was associated with an increased risk of NSCLC in all patients (OR=1.382; 95% CI=1.019‑1.875; P=0.037), and patients possessing the rs3787728 T/T major allele homozygote exhibited a 1.537‑fold greater risk with respect to developing lung squamous‑cell carcinoma (SCC) in all patients (95% CI=1.019‑2.318; P=0.0395). The CBR1 rs3787728 cytosine (C)/C allele homozygote was associated with a decreased risk of adenocarcinoma (ADC) in male patients (OR=0.633; 95% CI=0.413‑0.969; P=0.0348); however, no significant association was observed in CBR1 rs2835267 between SNPs and SCC or ADC‑type NSCLC. In conclusion, the results revealed that genetic polymorphisms of CBR1 rs3787728 were associated with susceptibility to NSCLC. Additional studies are required to identify the functional impact of CBR1 expression and activity in NSCLC.

View Figures

View References

1	Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 120:1290–1314. 2014. View Article : Google Scholar : PubMed/NCBI
2	He J and Chen W: 2012 Chinese cancer registry annual report. Military Medicine Society Press; Beijing: 2012
3	Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
4	Schwartz AG, Wenzlaff AS, Bock CH, Ruterbusch JJ, Chen W, Cote ML, Artis AS, Van Dyke AL, Land SJ, Harris CC, et al: Admixture mapping of lung cancer in 1812 African-Americans. Carcinogenesis. 32:312–317. 2011. View Article : Google Scholar : PubMed/NCBI
5	Marshall AL and Christiani DC: Genetic susceptibility to lung cancer-light at the end of the tunnel? Carcinogenesis. 34:487–502. 2013. View Article : Google Scholar : PubMed/NCBI
6	Oppermann U: Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol. 47:293–322. 2007. View Article : Google Scholar : PubMed/NCBI
7	Forrest GL and Gonzalez B: Carbonyl reductase. Chem Biol Interact. 129:21–40. 2000. View Article : Google Scholar : PubMed/NCBI
8	Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, et al: An unbiased cell morphology-based screen for new, biologically active small mol-ecules. PLoS Biol. 3:e1282005. View Article : Google Scholar : PubMed/NCBI
9	Tak E, Lee S, Lee J, Rashid MA, Kim YW, Park JH, Park WS, Shokat KM, Ha J and Kim SS: Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol. 54:328–339. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bains OS, Karkling MJ, Grigliatti TA, Reid RE and Riggs KW: Two nonsynonymous single nucleotide polymorphisms of human carbonyl reduct-ase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos. 37:1107–1114. 2009. View Article : Google Scholar : PubMed/NCBI
11	Murakami A, Yakabe K, Yoshidomi K, Sueoka K, Nawata S, Yokoyama Y, Tsuchida S, Al-Mulla F and Sugino N: Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelialmesenchymal transition and its clinical significance. Cancer Lett. 323:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
12	Varatharajan S, Abraham A, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, et al: Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol. 68:1577–1586. 2012. View Article : Google Scholar : PubMed/NCBI
13	Huang W, Ding L, Huang Q, Hu H, Liu S, Yang X, Hu X, Dang Y, Shen S, Li J, et al: Carbonyl reductase 1 as a novel target of (−)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology. 52:703–714. 2010. View Article : Google Scholar : PubMed/NCBI
14	Schlager JJ and Powis G: Cytosolic NAD (P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarettes moking and alcohol. Int J Cancer. 45:403–409. 1990. View Article : Google Scholar : PubMed/NCBI
15	Gu J, Shen Y and Zhang Y: Association between interleukin-4 polymorphisms and environment and non small cell lung cancer in Chinese population. J Cancer Res Ther. 10 Suppl:C135–C139. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Hua S, Zhang A, Kong X, Jiang C, Deng D and Wenlong B: Association between polymorphisms in COMT, PLCH1 and CYP17A1 and non-small cell lung cancer risk in Chinese nonsmokers. Clin Lung Cancer. 14:45–49. 2013. View Article : Google Scholar : PubMed/NCBI
17	Modesto JL, Hull A, Angstadt AY, Berg A, Gallagher CJ, Lazarus P and Muscat JE: NNK reduction pathway gene polymorphisms and risk of lung cancer. Mol Carcinog. 54 Suppl 1:E94–E102. 2015. View Article : Google Scholar : PubMed/NCBI
18	Waclawik A, Jabbour HN, Blitek A and Ziecik AJ: Estradiol-17beta, prostaglandin E2 (PGE2) and the PGE2 receptor are involved in PGE2 positive feedback loop in the porcine endometrium. Endocrinology. 150:3823–3832. 2009. View Article : Google Scholar : PubMed/NCBI
19	Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F and Mizunuma H: Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther. 6:1379–1386. 2007. View Article : Google Scholar : PubMed/NCBI
20	Jain S, Chakraborty G, Raja R, Kale S and Kundu GC: Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res. 68:7750–7759. 2008. View Article : Google Scholar : PubMed/NCBI
21	Takenaka K, Ogawa E, Oyanagi H, Wada H and Tanaka F: Carbonyl reductase expression and its clinical significance in non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev. 14:1972–1975. 2005. View Article : Google Scholar : PubMed/NCBI
22	Makrilia N, Lappa T, Xyla V, Nikolaidis I and Syrigos K: The role of angiogenesis in solid tumours: An overview. Eur J Intern Med. 20:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
23	Kalabus JL, Cheng Q, Jamil RG, Schuetz EG and Blanco JG: Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene. Toxicol Lett. 211:266–273. 2012. View Article : Google Scholar : PubMed/NCBI
24	American Cancer Society, . Tobacco and cancer. http://www.cancer.org/cancer/cancercauses/tobaccocancer/questionsaboutsmokingtobaccoandhealth/Accessed. October 20–2014.
25	Hockley SL, Arlt VM, Brewer D, Te Poele R, Workman P, Giddings I and Phillips DH: AHR- and DNA damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. Chem Res Toxicol. 20:1797–1810. 2007. View Article : Google Scholar : PubMed/NCBI
26	Atalla A, Breyer-Pfaff U and Maser E: Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica. 30:755–769. 2000. View Article : Google Scholar : PubMed/NCBI
27	Breyer-Pfaff U, Martin HJ, Ernst M and Maser E: Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver. Drug Metab Dispos. 32:915–922. 2004.PubMed/NCBI